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 2 
ABSTRACT 24 
 Many viruses have evolved mechanisms to evade the repression of translation 25 
mediated by protein kinase R (PKR).  In the case of murine cytomegalovirus (MCMV), 26 
the protein products of two essential genes, m142 and m143, bind to dsRNA and block 27 
phosphorylation of PKR and eukaryotic initiation factor 2. A distinctive feature of 28 
MCMV is that two proteins are required to block PKR activation whereas other viral 29 
dsRNA-binding proteins that prevent PKR activation contain all the necessary functions 30 
in a single protein.  In order to better understand the mechanism by which MCMV evades 31 
the PKR response, we investigated the associations of pm142 and pm143 with each other 32 
and with PKR.  Both pm142 and pm143 interact with PKR in infected and transfected 33 
cells. However, the ~200 kDa pm142:pm143 complex that forms in these cells does not 34 
contain substantial amounts of PKR, suggesting that the interactions between 35 
pm142:pm143 and PKR are unstable or transient.  The stable, soluble pm142:pm143 36 
complex appears to be a heterotetramer consisting of two molecules of pm142 associated 37 
with each other and each one binding to and stabilizing a monomer of pm143.  MCMV 38 
infection also causes relocalization of PKR into the nucleus and to an insoluble 39 
cytoplasmic compartment.  These results suggest a model in which the pm142:pm143 40 
multimer interacts with PKR and causes its sequestration in cellular compartments where 41 
it is unable to shut off translation and repress viral replication. 42 
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INTRODUCTION 43 
As a consequence of the threat viruses pose to the survival and fitness of their 44 
hosts, an array of cellular defenses have evolved to repress viral infection.  In mammals, 45 
the interferon system mediates multi-faceted innate immune responses to viral infections 46 
(25).  Among the important effectors of this system is the interferon-stimulated double 47 
stranded RNA (dsRNA)-activated protein kinase R (PKR).  dsRNA, which is produced 48 
during many viral infections (29), binds to PKR, causing a conformational change, 49 
dimerization, and autophosphorylation followed by phosphorylation of the alpha subunit 50 
of initiation factor 2 (eIF2).  Phosphorylated eIF2 inhibits the activity of the guanine 51 
nucleotide exchange factor eIF2B, resulting in repression of translation initiation (8).     52 
Because viral replication depends on ongoing translation, viruses have evolved a 53 
variety of mechanisms for evading the PKR response (22).  One such mechanism utilizes 54 
virally encoded dsRNA-binding proteins such as the E3L protein of vaccinia virus and 55 
the NS1 protein of influenza virus.  The observation that vaccinia virus lacking E3L 56 
(VVE3L) has a very limited host range in cell culture and is avirulent in animals but 57 
does replicate in PKR-deficient cells illustrates the importance of blocking the PKR 58 
response (3, 30, 31).  Many viral dsRNA-binding proteins form homodimers and bind to 59 
PKR, but the relative contributions of the various interactions to anti-PKR functions vary.  60 
For example, in the case of E3L, binding to and sequestering dsRNA may be sufficient to 61 
prevent PKR activation (5), while in the case of NS1, direct binding to PKR appears to be 62 
more critical than binding to dsRNA (20).   63 
In previous studies, we identified dsRNA-binding proteins encoded by two  64 
herpesviruses, human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) 65 
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(6, 7).  The TRS1 and IRS1 genes of HCMV each encode proteins that block PKR 66 
activation by a mechanism that appears to depend on binding to both dsRNA and PKR 67 
(10, 11).  These proteins also have the unusual property that they cause accumulation of 68 
PKR in the nucleus.  69 
In the case of MCMV, the m142 and m143 genes function by blocking PKR 70 
activation.  Valchanova and coworkers reported that the failure of mutant viruses lacking 71 
either m142 or m143 to replicate is linked to activation of PKR and inhibition of protein 72 
synthesis (27).  We found that the protein products of these two genes (pm142 and 73 
pm143) co-immunoprecipitate in infected cells and function together to bind dsRNA and 74 
to enable replication of VVE3L (7).  Thus, the MCMV system differs from other viral 75 
systems studied thus far in that two different proteins are required to block PKR 76 
activation.   77 
The limited understanding of how dsRNA binding proteins actually block PKR 78 
function coupled with the unusual features of the MCMV system led us to undertake 79 
studies aiming to clarify the interactions among pm142, pm143 and PKR.  We found that 80 
like other well-studied viral dsRNA binding proteins, pm142 and pm143 each can bind to 81 
PKR.  Pm142 and pm143 appear to form a stable soluble heterotetrameric complex, 82 
which, interestingly, does not contain substantial amounts of PKR.  Similar to HCMV, 83 
MCMV infection also causes relocalization of PKR to the nucleus, as well as to insoluble 84 
cytoplasmic complexes.  These results suggest a model in which interaction with pm142 85 
and pm143 results in PKR sequestration into compartments where it is unable to shut off 86 
protein synthesis.  87 
 88 
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MATERIALS and METHODS 89 
Cells, virus, and infections.  NIH 3T3 cells, PKR null mouse fibroblasts (provided by 90 
Bryan Williams, Cleveland Clinic Foundation), and HeLa cells were maintained in 91 
Dulbecco’s modified Eagle’s medium supplemented with 10% NuSerum (Collaborative 92 
Biomedical) as previously described (6).  MCMV strain K181 and MCMV MC.55, a 93 
recombinant of a strain derived from K181 that expresses green fluorescent protein (GFP) 94 
(provided by Jeff Vieira, University of Washington (28)) were propagated in NIH 3T3 95 
cells.  Infections were performed at a multiplicity of infection (MOI) of 3. 96 
 97 
Plasmids.  The plasmid pCS2+BirA which expresses E. coli biotin ligase was obtained 98 
from Bruce Clurman (Fred Hutchinson Cancer Research Center).  All other expression 99 
constructs used in these experiments were cloned into the pcDNA3.1/V5-His-TOPO 100 
vector (Invitrogen). 101 
Plasmid pEQ1100, which expresses EGFP with a C-terminal biotinylation signal 102 
and adjacent 6 x His tag (hereafter designated by –B and –H, respectively) was 103 
previously described (7). The plasmid pEQ1068 (TRS1[1–738]-B-H) was constructed by 104 
inserting primers encoding a biotinlylation signal (7) into the XhoI and XbaI sites of 105 
pEQ979 (10).   106 
Construction of pEQ1073 (m142-B-H) was previously described (7).  pEQ1163 107 
(m142-B) was derived from pEQ1073 by digestion with Pme1 and Age1, blunting with 108 
Klenow, and religating to remove the His tag.  pEQ1063 (m142-H) was made by 109 
amplification of pEQ985 (7) using oligos #461 (ACCATGGACGCCCTGTGCGC) and 110 
#548 (GTCGTCATCGTCGGCGTCCGC) and cloning into the TOPO vector.    111 
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PEQ1109 (m143-H) was made by amplification of pEQ939 (7) using oligos #410 112 
(ACCATGTCTTGGGTGACCGGAGAT) and #596 (CGCGTCGGTCGCTCTCTCGT) 113 
and cloning into the TOPO vector .  The m143 ORF was removed from pEQ1109 by 114 
digestion with HindIII and EcoRV and cloned into pEQ1068 after digestion with the 115 
same enzymes to construct pEQ1126 (m143-B-H).  PEQ1164 (m143-B) was derived 116 
from pEQ1126 by digestion with Pme1 and Age1, blunting, and religating.   117 
 118 
Transient transfection.  Sub-confluent HeLa cells in 12 well plates were transfected 119 
with plasmid DNA using Lipofectamine 2000 reagent (Invitrogen) according to the 120 
manufacturer’s instructions.  Biotin (25 µM) was added to the medium following 121 
transfection.  At 24 to 48 h post-transfection the cells were washed with PBS at 4°C then 122 
lysed in 300 µl of RIPA buffer (50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.2% SDS, 123 
1% NaDOC) containing 250 mM NaCl.  After reserving a portion for subsequent 124 
analysis, the resulting lysates were used for binding to avidin as described below.  125 
 126 
Immunoprecipitation, avidin agarose pull-down, and immunoblot analyses.  For co-127 
immunoprecipitation analyses, NIH 3T3 cells in 6 well plates were either mock-infected 128 
or infected with MCMV MC.55.  At 48 h post-infection the cells were washed twice with 129 
PBS (4°C), then lysed in 300 µl of NP-40 lysis buffer (50 mM Tris.Cl (pH 7.5), 150 mM 130 
NaCl, 1% NP-40).  The cells were incubated on a rotator for 20 min., then clarified by 131 
centrifugation at 16,000 x g for 10 min. at 4°C.  3% of the sample was saved for 132 
assessing protein expression in the lysates. The remaining supernatants were transferred 133 
to new tubes, and 5µl of the indicated rabbit polyclonal antiserum (pre-immune, anti-134 
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m142, or anti-m143; provided by Laura Hanson and Ann Campbell, Eastern Virginia 135 
Medical School (12)) was added.  After 1-2 h on the rotator, protein A sepharose was 136 
added to each tube, and rotation was continued for ~ 4 h.  The samples were washed three 137 
times with NP-40 lysis buffer, followed by separation on 10% polyacrylamide gels and 138 
transfer to polyvinylidene difluoride (PVDF) membranes by electroblotting.  The 139 
membranes were probed with a mixture of m142 and m143 antisera or with mouse 140 
monoclonal antibody PKR (B-10) (#sc-6282, Santa Cruz Biotechnology). 141 
              For avidin (AV) agarose binding assays, transfected cell lysates were incubated 142 
with immobilized avidin (PIERCE) for 2-4 h, washed four times, then immunoblotted as 143 
described above.  Blots were probed with either Penta·His antibody (QIAGEN) or avidin-144 
AP (Avidx-AP conjugate; Applied Biosystems) according to the manufacturer’s 145 
recommendations.   146 
For all immunoblot analyses, proteins were detected using the Western-Star™ 147 
chemiluminescent detection system (Applied Biosystems) according to the 148 
manufacturer’s recommendations.  Silver staining was performed using the 149 
SilverQuest™ silver staining kit (Invitrogen) according to the manufacturer’s 150 
recommendations. 151 
 152 
Metabolic labeling.  For pulse-chase analysis, HeLa cells were transfected as described 153 
above with pCS2+BirA and either m143-B-H alone, or m143-B-H and m142-H.  24 h 154 
later, the cells were labeled for 1 h with 100 µCi/ml [35S]-methionine (Easytag™ express 155 
protein labeling mix, PerkinElmer) and, after washing twice, chased by addition of 156 
medium containing 1 mM cold methionine.   At the indicated times post-chase the cells 157 
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were lysed with 300 µl of RIPA buffer containing 250 mM NaCl, and the resulting 158 
lysates incubated in the presence of AV-agarose as described above.  The resulting 159 
samples were separated on 10% polyacrylamide gels, dried, and subjected to 160 
phosphorimager analysis on a Typhoon Trio multi-mode imager. 161 
 162 
Cell fractionation.  For glycerol gradient fractionation of infected cells, 100 mm dishes 163 
of NIH 3T3 cells were infected with MCMV MC.55.  At 48 h post-infection the cells 164 
were scraped into PBS, pelleted, then resuspended in 250 µl of cell fractionation buffer 165 
(20 mM Hepes (pH 8.0), 150 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 1% NP-40, 1 mM 166 
benzamidine, 10% glycerol).  The samples were incubated for 30 min., 4°C on a rotator, 167 
then clarified by centrifugation (16,000 x g).  Supernatants were separated on 5 ml 15-168 
35% glycerol gradients at 237,000 x g, 17 h, 4°C.  Fractions were collected from the 169 
bottom of the gradients and separated on 10% polyacrylamide gels, transferred to PVDF, 170 
probed with a mixture of m142 and m143 antisera, then stripped and re-probed with anti-171 
PKR antiserum. Molecular weight standards were centrifuged on parallel gradients, and 172 
their distribution was determined by polyacrylamide gel electrophoresis and Coomassie 173 
blue staining.    174 
 Similar glycerol gradient fractionation of transfected cells was performed after 175 
transfection of plasmids expressing m142-B-H and m143-B-H into HeLa cells.  Lysates 176 
prepared at 24 h post-transfection were analyzed as described for infected cells, except 177 
that the PVDF membrane was probed with avidin-AP for protein detection.  178 
Nuclear- and cytoplasmic-enriched fractions were prepared from 100 mm dishes 179 
of NIH 3T3 cells after mock-infection or infection with MCMV MC.55.  At 24, 48, and 180 
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72 h post-infection, the cells were washed with PBS and lysed with 1 ml of cell 181 
fractionation buffer (see above).  The lysates were transferred to 1.5 ml microfuge tubes, 182 
and placed on a rotator at 4°C for 30 min.  The samples were then centrifuged at 1000 x 183 
g, 5 min., 4°C, and the supernatant (cytoplasmic-enriched fraction) removed carefully 184 
without disturbing the pellet.  The pellet fraction was then gently resuspended in 0.5 ml 185 
of fractionation buffer, microfuged as before, and the remaining pellet (nuclear-enriched 186 
fraction) resuspended in 60 µl of 2% SDS and sonicated to shear DNA.  Equal amounts 187 
of protein were separated on 10% polyacrylamide gels, transferred to PVDF, and 188 
immunoblotted with the following antisera according to the manufacturer’s 189 
recommendations:  PKR (B-10), lamin A/C (#2032, Cell Signaling), calnexin (#610523, 190 
BD Transduction Laboratories), ß-actin (#A2066, Sigma). and a mixture of m142 and 191 
m143 antisera. 192 
 193 
Immunofluorescence.  NIH 3T3 cells or PKR null mouse fibroblasts grown on glass 194 
coverslips were mock-infected or infected with MCMV K181.  At 48 h post-infection the 195 
cells were washed three times with PBS (4°C), fixed in 100% MeOH at -20°C for 5 min., 196 
then washed again with PBS.  The coverslips were blocked with 5% normal goat serum 197 
for 1 h, then incubated for 1 h with PKR (B-10) antibody or an anti-ß-Gal antibody 198 
(Promega) that served as an IgG2a isotype control.  The coverslips were washed three 199 
times with PBS, then incubated with FITC-conjugated anti-mouse secondary antibody 200 
(SIGMA) for 1 h in the dark.  After washing the cells three times with PBS they were 201 
incubated with Hoechst 33342 (5 µg/ml; Invitrogen) for 5 min., washed twice with PBS, 202 
then mounted on slides using ProLong Gold anti-fade mounting medium (Invitrogen).  203 
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All incubations were performed at room temperature.  The samples were analyzed using a 204 
Deltavision RT Wide-field Deconvolution Microscope (Applied Precision, Inc.).  205 
 206 
RESULTS 207 
pm142 and pm143 form a complex that binds to PKR in MCMV-infected cells.  208 
Several viral proteins that block PKR activation bind to both dsRNA and PKR (4, 5, 10, 209 
11, 16, 20, 24). We have shown that MCMV pm142 and pm143 together bind to dsRNA 210 
and block PKR activation (7).  Therefore, as a next step in elucidating the mechanism by 211 
which pm142 and pm143 function, we investigated whether they also physically 212 
associate with PKR.   213 
 First, we infected NIH 3T3 cells with MCMV and at 48 h post-infection prepared 214 
lysates.  After immunoprecipitation with pre-immune serum or antisera specific for either 215 
pm142 or pm143, we analyzed the precipitated proteins by immunoblot analyses using 216 
either a mixture of rabbit anti-m142 and anti-m143 antisera or with a mouse monoclonal 217 
antibody directed against PKR (Fig. 1).  Although the immunoglobulin heavy chain 218 
partially obscured the pm142 band following precipitation of MCMV-infected lysates 219 
with anti-m142 or anti-m143 antiserum, these experiments confirmed that pm142 and 220 
pm143 form a complex as previously reported (7).  Also, as noted previously, anti-m143 221 
appeared to precipitate more pm142 compared to the amount of pm143 precipitated by 222 
anti-m142 (compare lanes 7 and 8 in Fig. 1A).  Importantly, pm142 and pm143 antisera 223 
each precipitated PKR while preimmune serum did not (Fig 1B).  The amount of PKR 224 
that co-immunoprecipitated with pm142 or pm143 was relatively small, suggesting the 225 
possibility that only a minority of PKR in the cell is associated with these two proteins 226 
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(see below).  As expected, pm142, pm143 and PKR were absent from precipitates from 227 
mock-infected cell lysates after precipitation with the same antisera.  Thus, PKR 228 
associates with pm142 and pm143 in MCMV-infected cells.        229 
 230 
pm142 and pm143 each bind to PKR in transfected HeLa cells.  In order to determine 231 
which of the MCMV proteins (pm142, pm143, or both) associates with PKR, we used an 232 
AV-agarose pull-down system as described in Materials and Methods.  This system takes 233 
advantage of the high affinity of the biotin-avidin interaction and eliminates background 234 
resulting from the immunoglobulin heavy chain.  The plasmids used in these assays 235 
expressed proteins that were either His-tagged (designated pm142-H, for example), or 236 
contained a 14 amino acid biotinylation signal in addition to the His tag (e.g. pm142-B-237 
H).  When co-transfected into cells along with a plasmid containing the  E.  coli biotin 238 
ligase (BirA) gene and incubated in the presence of 25 µM biotin, biotin is efficiently 239 
added to a lysine residue in the biotinylation signal of signal-tagged proteins (2).  240 
For these analyses, we transfected HeLa cells with various combinations of 241 
expression plasmids, prepared lysates at 48 h post-transfection, and detected proteins 242 
present in the total lysates and in the fractions that bound to AV-agarose by assays using 243 
anti-His or avidin-AP. When probed with anti-His antibody, all of the His-tagged proteins 244 
were detected in the lysates (Fig. 2A, top panel). Consistent with the known interactions 245 
of pm142 and pm143, both proteins were detected in the AV bead-bound fractions when 246 
either one was biotinylated (Fig 2A, bottom panel, lanes 2 and 3), while neither protein 247 
bound to EGFP-B-H (lanes 7 and 8), even on a longer exposure (data not shown).  248 
Omitting the BirA plasmid from the transfection eliminated the binding of pm142 or 249 
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pm143 to the AV beads (lane 4).  Note that the biotinylation signal caused a slight but 250 
detectable increase in the size of the pm142 and pm143 proteins (compare lanes 2 and 3).   251 
 Immunoblot assays of the same samples using PKR antiserum revealed that at 252 
least a small amount of PKR was precipitated by the pm142:pm143 complex and by 253 
pm142 and pm143 individually (Fig 2B, lanes 2, 3, 5, and 6). pTRS1-B-H also 254 
precipitated PKR (lane 1), consistent with our previous finding that pTRS1 binds to PKR 255 
(11). As expected, the negative controls (samples lacking BirA or pulled down with 256 
EGFP-B-H) did not precipitate PKR (lanes 4, 7 and 8). Treatment of the 257 
immunoprecipitated material with dsRNA-specific RNase (RNaseIII) under conditions 258 
that completely digested reovirus genomic dsRNA, did not disrupt the association of 259 
pm143 with pm142 or with PKR (data not shown). However, dsRNA that is embedded in 260 
the complex might not be accessible to the RNaseIII, so these results do not exclude the 261 
possibility that dsRNA is a key component of the complex.  However, these data do 262 
reveal that pm142 and pm143 each appear to bind to PKR independently.   263 
 264 
Expression of pm142 stabilizes pm143.  We noticed that the abundance of pm143 in 265 
lysates was consistently much lower when it was expressed by itself or with EGFP than 266 
when expressed with pm142 (e.g. compare lanes 6 and 8 to lanes 2, 3, and 4 in Fig. 2A, 267 
top panel).  To evaluate the possibility that pm143 might be stabilized by its association 268 
with pm142, we measured the half-life of pm143 in cells transfected with pm143-B-H in 269 
the presence or absence of pm142-H (Fig. 3).  At 24 h post-transfection, we pulse-labeled 270 
cells with [35S]-methionine for 1 h, then chased with excess cold methionine and 271 
analyzed proteins bound to AV-agarose by electrophoresis and phosphorimager analysis.  272 
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As is evident in Fig. 3, even by two hours post-chase there was substantially less pm143 273 
in the absence of pm142 than when the proteins were co-expressed.  The calculated half-274 
life of pm143 was approximately 8 h in the absence of pm142 and 25 h when expressed 275 
in combination with pm142.  Thus, pm143 is stabilized by coexpression of pm142. 276 
 277 
The pm142:pm143 complex is larger than a heterodimer but lacks substantial 278 
amounts of PKR.  The observation that pm142 and pm143 bind to each other and that 279 
both also bind to PKR (Figs. 1 and 2) suggested that these three proteins might form a 280 
heterotrimeric complex in infected cells.  To test this hypothesis, we fractionated infected 281 
cell lysates over glycerol gradients and analyzed the distribution of these three proteins 282 
by SDS-PAGE and immunoblot assays (Fig. 4).  In parallel gradients, we fractionated 283 
molecular weight standards in an identical manner and determined their distribution by 284 
polyacrylamide gel electrophoresis and Coomassie Blue staining. 285 
Most of the pm143 migrated with a peak of pm142 at an apparent size of ~200 286 
kDa (Fig. 4A, fractions 12 - 17), which is close to the calculated size (178 kDa) of a 287 
heterotrimer consisting of one molecular each of pm142 (49 kDa), pm143 (61 kDa) and 288 
PKR (68 kDa).  Surprisingly, we detected little or no PKR in the fractions containing the 289 
pm142:pm143 complex (Fig 4B).  Instead, PKR migrated mostly in the range of ~70 kDa 290 
to ~160 kDa (fractions 17 – 24).  The smaller size within this range corresponds to that  291 
of the PKR monomer (68 kDa), while the larger species could represent PKR dimers or 292 
PKR bound to other factors.  Although the small amount of overlap between pm142, 293 
pm143, and PKR (fractions 16-18) might represent PKR:pm142:pm143 heterotrimers, 294 
these results indicate that the majority of the pm142:pm143 complex in infected cells is 295 
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not bound to PKR.  Conversely, most of the PKR in the cell appears not to be bound to 296 
the pm142:pm143 complex, which may explain the low amount of PKR associating with 297 
pm142 and pm143 in our immunoprecipitation experiments (Figs. 1 and 2).  However, 298 
these data do not exclude the possibility that there is a PKR:pm142:pm143 trimeric 299 
complex in infected cells but that it dissociates under the conditions of these experiments.  300 
In addition to its presence in the pm142:pm143 complexes, pm142 migrates as a 301 
smaller species, possibly representing pm142 monomers and homodimers (see below), as 302 
well as in larger complexes of unknown composition. Perhaps due to its labile nature in 303 
the absence of pm142 (Fig. 3), pm143 is present only in fractions containing pm142.    304 
These results, suggesting that there is a stable ~200 kDa complex consisting of 305 
pm142 and pm143 that lacks substantial amounts of PKR, raise two questions.  First, 306 
what is the composition of the ~200 kDa complex?   Second, can we reconcile the 307 
observations that pm142 and pm143 can each bind to PKR and prevent its activation yet 308 
most of the PKR in the cells appears not to be stably associated with pm142 and pm143?  309 
The subsequent studies were designed to evaluate these issues.  310 
 311 
The pm142:pm143 complex lacks other proteins.  Since the pm142:pm143 complex 312 
migrated at a size of ~200 kDa (Fig. 4) and a heterodimer of the two proteins would be 313 
expected to be only ~110 kDa, we investigated the possibility that the complex contains 314 
additional proteins.  First, we transfected cells with plasmids expressing pm142-B-H and 315 
pm143-B-H, and at 24 h post-transfection prepared cytoplasmic lysates and analyzed the 316 
distribution of the proteins by glycerol gradient centrifugation. Detection of the two 317 
transfected proteins using avidin-AP demonstrated that, similar to the complex present in 318 
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infected cells, the pm142:pm143 multimer sedimented as a ~200 kDa complex in these 319 
transfected, uninfected cells (Fig. 5).  This result demonstrates that no other MCMV 320 
proteins are required for formation of the major pm142:pm143 complex. 321 
 To evaluate whether any cellular proteins were present in the pm142:pm143 322 
multimer, we transfected cells with pm142-H and pm143-B-H and pulled-down pm143-323 
B-H and any associated proteins by binding to AV-agarose.  We then detected these 324 
proteins by gel electrophoresis followed by silver staining.  As a negative control we 325 
analyzed lysates from cells transfected with pm142-H and pm143-H, both lacking the 326 
biotinylation signal.  For comparison, we also analyzed HCMV pTRS1-H-B. Consistent 327 
with prior evaluations using immunoblot assays, pm142 was detectable in the pm143-328 
bound material (Fig. 6).  Although there were several other minor protein bands, some of 329 
which also were detected in the negative control sample, none approached the abundance 330 
of the bands corresponding to pm142 and pm143.   Thus, the relatively large size of the 331 
pm142:pm143 multimer cannot easily be explained by the presence of either additional 332 
MCMV or cellular proteins. 333 
 334 
The pm142:pm143 complex may be a heterotetramer.  The absence of other proteins 335 
in the pm142:pm143 complex might be explained by its being a higher order multimer of 336 
just these two proteins  To investigate this possibility, we again transfected various 337 
plasmids expressing proteins tagged with either His or the biotinylation signal into HeLa 338 
cells and assayed total and AV-bound proteins using either anti-His antibody or avidin-339 
AP.   340 
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 When expressed by itself, pm142-B was detectable in lysates and the AV-bound 341 
samples using avidin-AP, but not with anti-His (Fig. 7, panels A-D, lanes 1).  On the 342 
other hand, pm142-H was expressed in lysates (A, lane 2), but it lacks the biotin tag and 343 
so, as expected, did not bind to AV-agarose (B, lane 2) nor was it detected by avidin-AP 344 
(C and D, lanes 2).  However, when pm142-B and pm142-H were co-transfected, pm142-345 
H was pulled down by AV beads (B, lane 3), demonstrating that pm142-H binds to 346 
pm142-B, thus suggesting that pm142 can homodimerize.  347 
Consistent with its relative instability in the absence of pm142 (Fig. 3), pm143-B 348 
transfection by itself resulted in only a faint band in both the lysates and bound fractions 349 
(C and D, lanes 4). On an exposure comparable to that shown in panels C and D, pm143-350 
H was almost undetectable (not shown) but with a longer exposure it was clearly present 351 
(A, lane 5). In lysates prepared after transfection of both pm143-B and pm143-H, we 352 
could detect both proteins in the lysates but only pm143-B in the bound fraction.  The 353 
observation that all of the other proteins shown Fig. 7 that bound directly or indirectly to 354 
AV beads produced bands that appeared at least as intense in bound samples as in the 355 
lysates, coupled with the detection of pm143-H in the lysates but not the bound samples, 356 
suggests that pm143 does not self-associate.  357 
Interestingly, when pm142-H was expressed along with pm143-B and pm143-H, 358 
pm143-H was present in the bound fraction along with pm142-H (Fig. 7B, lane 7).  This 359 
result indicates that pm143-B and pm143-H were tethered together by one or more 360 
molecules of pm142.  The absence of detectable pm142-H or pm143-H binding to the 361 
EGFP-B-H control (lane 8, B) supports the specificity of the binding reactions. 362 
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 Collectively, the results of Figs. 3-6 suggest that the major form of the 363 
pm142:pm143 complex is a heterotetramer in which two pm142 molecules bind to each 364 
other in addition to each binding to separate pm143 monomers.   365 
 366 
MCMV causes relocalization of PKR.  We previously reported that pTRS1 and pIRS1 367 
not only bind to PKR, but that they also cause accumulation of PKR in the nucleus (11).  368 
Because of the similarities between HCMV and MCMV, we hypothesized that MCMV 369 
infection might also cause PKR relocalization.  To test this idea, we prepared nuclear- 370 
and cytoplasmic-enriched fractions of mock- or MCMV-infected NIH 3T3 cells at 24, 48, 371 
and 72 h post-infection and evaluated the distribution of PKR by immunoblot analysis 372 
(Fig. 8).  PKR remained relatively constant in abundance and remained predominantly 373 
cytoplasmic during this time interval in mock-infected cells.  In contrast, its abundance 374 
increased and it redistributed to the nuclear fraction in MCMV-infected cells.  We 375 
performed control immunoblots on the same cytoplasmic and nuclear extracts to evaluate 376 
the efficacy of the fractionation procedure.  Antibodies directed against the nuclear 377 
marker lamin A/C revealed its presence exclusively in the nuclear fraction. The 378 
cytoplasmic marker calnexin was upregulated by MCMV infection, but remained 379 
predominantly cytoplasmic in the infected cells.  An anti-ß-actin immunoblot showed that 380 
the abundance of ß-actin was similar in mock-infected and infected cells, although it 381 
appeared to be slightly more concentrated in the nuclear than the cytoplasmic fractions in 382 
both cases.  The same extracts were also probed with a mixture of anti-m142 and anti-383 
m143 antisera, and as reported by Hanson et al. (12), pm142 and pm143 were present in 384 
both the cytoplasmic and nuclear fractions throughout infection.    385 
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 As a complementary method for assessing the effects of MCMV on PKR, we 386 
examined the distribution of PKR in mock- and MCMV-infected cells by indirect 387 
immunofluorescence using an Olympus DeltaVision microscope as described in 388 
Materials and Methods.  In mock-infected NIH 3T3 cells (Fig. 9, panel A), incubation 389 
with anti-PKR antibody showed the predominantly cytoplasmic localization of PKR with 390 
a small amount of nuclear PKR appearing to localize in the nucleoli, as has been reported 391 
by others (14, 15) and consistent with our immunoblot data (Fig. 8).  At 48 h post 392 
infection, PKR expression was elevated in MCMV-infected cells and a substantially 393 
higher amount was detectable in the nucleus.  Surprisingly, contrary to the results based 394 
on cell fractionation methods (Fig. 8), the majority of the PKR in the infected cells 395 
appeared to remain localized within the cytoplasm.  The PKR signal in infected cells also 396 
seemed distributed in a coarser punctate pattern in the cytoplasm of infected cells 397 
compared to mock-infected cells.  Staining with an isotype-matched control antibody 398 
showed minimal background staining in these cells.  As an additional control, we 399 
incubated mock- or MCMV-infected PKR-null MEFs with anti-PKR antiserum or the 400 
isotype-matched control antibody (Fig. 9B). In these cells, both the anti-PKR and control 401 
antibodies revealed only a low level of background fluorescence.   402 
 Thus, the results of the immunoblot assays and immunofluorescence assays both 403 
revealed an increase in the amount of nuclear PKR after MCMV infection.  Compared to 404 
the immunoblot assays, the immunofluorescence studies indicate that there is more 405 
abundant PKR in the cytoplasm at late times post infection.  These results suggest that 406 
MCMV infection results in relocalization of PKR to both the nucleus and to insoluble 407 
cytoplasmic complexes. 408 
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 409 
DISCUSSION 410 
 The importance of PKR as a mediator of intracellular innate defenses against viral 411 
infections is highlighted by the remarkable number and diversity of viral factors and 412 
mechanisms that have evolved to counteract its inhibitory effects on host cell translation 413 
(22).  In several viral systems, mutants lacking anti-PKR factors are severely attenuated 414 
for growth in cell culture and have extremely reduced virulence in animal models.  415 
Moreover, the replication defect of some of these viruses has been shown to be reversed 416 
at least in part in PKR-deficient cells and, in the case of herpes simplex type-1, even in 417 
animals, thus providing genetic support for the functional importance of the interactions 418 
between PKR and viral antagonists (19, 30, 31).  419 
 Many viruses encode a dsRNA-binding protein that can inhibit the PKR pathway. 420 
Some viruses, including vaccinia virus, herpes simplex type 1 and HCMV, have been 421 
shown to contain a second gene that also inhibits the PKR pathway (4, 6, 16, 22, 26).  In 422 
these examples, the two genes act independently and, in the vaccinia virus and herpes 423 
simplex type 1 cases, at different steps in the PKR activation pathway.  The two HCMV 424 
genes are very closely related and likely act at the same step.  MCMV also has two anti-425 
PKR genes but is unusual in that the two genes act together as a single functional unit.  426 
Both m142 and m143 are required for effective dsRNA binding and for rescue of 427 
VVE3L replication (7).  Furthermore, deletion of either gene results in phosphorylation 428 
of PKR and eIF2, repression of protein synthesis in infected cells, and eliminates 429 
MCMV replication (27).  The genomic proximity of m142 and m143 combined with their 430 
functional similarities suggest that evolution of MCMV may have resulted in separation 431 
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of the functions needed for blocking PKR into two proteins, while in other viruses these 432 
functions are combined in a single protein.   433 
 Many well-studied viral dsRNA-binding proteins that prevent PKR activation 434 
bind to PKR (4, 11, 20, 24).  We found that the pm142:pm143 complex does so as well 435 
(Fig. 1).  The observation that pm142 and pm143 can each bind to PKR in transfection 436 
assays (Fig. 2) argues against the possibility that the separation of dsRNA-binding 437 
protein functions in MCMV led to one protein becoming specialized in binding to PKR.  438 
We do not know whether the interactions between pm142:pm143 and PKR are direct 439 
ones.  Data showing that pm142 and pm143 are each able to bind to PKR, yet the 440 
combination of both is required for strong binding to dsRNA (7), suggest that a dsRNA 441 
tether is not required for PKR binding to pm142 or pm143, but it remains possible that 442 
there are other proteins or nucleic acids contributing to the interaction.  443 
 We also do not yet know whether binding to PKR is required for pm142:pm143 444 
function, although based on studies of other viral dsRNA-binding proteins we suspect 445 
that it is.  HCMV pTRS1 (and pIRS1) and influenza NS1 bind to PKR, and these 446 
interactions appear to be essential for its inhibition (12, 20).  In the case of vaccinia virus 447 
E3L, the C-terminal dsRNA binding domain, in the absence of the N-terminal PKR-448 
binding domain, is sufficient for viral replication in many cell types but it is required for 449 
preventing PKR activation late in infection (18), for blocking the inhibitory effects of 450 
PKR in a yeast growth assay (24), and for virulence in animal models (3). Evaluating 451 
whether E3L function requires it to bind to PKR is complicated by the presence of other 452 
functions, including an N-terminal Z-DNA binding domain that may be responsible for 453 
some of the observed phenotypes (17). Adding to the complexity, binding to PKR does 454 
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not always inhibit PKR function, as is clearly illustrated by the activation of PKR 455 
resulting from its interaction with the cellular regulator PACT (21).  Nonetheless, the fact 456 
that both pm142 and pm143 associate with and inhibit PKR does suggest that this is a 457 
functionally important physical interaction.  458 
 The observed binding of pm142, pm143 and PKR to each other in each binary 459 
combination suggested that these three proteins might form a heterotrimeric complex.  460 
Although we found clear evidence for a complex of pm142 and pm143 in infected or 461 
transfected cells, little if any PKR co-migrated with the pm142:pm143 complex.  One 462 
possible explanation for the observed interaction between PKR and pm142:pm143 by 463 
coimmunoprecipitation but not by glycerol gradient fractionation is that the interaction is 464 
unstable and therefore the complex dissociated under the conditions used in the glycerol 465 
gradient experiments.  Alternatively, the interaction might be a transient one, possibly 466 
resulting in inactivation of PKR by a mechanism that does not require continued 467 
association with the MCMV proteins.  468 
 We also discovered that MCMV alters the distribution of PKR in infected cells.  469 
Our analyses of uninfected cells are consistent with reports indicating that approximately 470 
20% of the cellular PKR is present in the nucleus, usually in association with the 471 
nucleolus (14, 15).  Fractionating cells with detergent revealed accumulation of PKR in 472 
the nuclear-enriched pellet fraction by 24 h post infection (Fig.8).  Since such pellet 473 
fractions may also contain insoluble cytoplasmic material, complementary methods are 474 
important for evaluating protein distribution.  Using immunofluorescence assays, we 475 
found that PKR did indeed appear to accumulate in the nucleus during infection, but a 476 
large fraction of it remained in the cytoplasm.  PKR accumulates in the nucleus after 477 
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HCMV infection but not after vaccinia infection (11).  Using recombinant vaccinia 478 
viruses, we showed that pTRS1 or pIRS1 could mediate this relocalization, suggesting 479 
that pm142 and pm143 are plausible candidates for instigating the redistribution of PKR 480 
during MCMV infection.   481 
 Altered distribution of PKR has been reported in other settings.  ER stress can 482 
cause PKR to accumulate in the nucleus (23). Activated PKR was recently shown to be 483 
enriched in the nucleus of high risk myelodysplastic syndrome lymphoblasts (9) and in 484 
neurons expressing the human immunodeficiency virus type I gp120 where it may 485 
contribute to neurodegeneration (1). Human papilloma virus causes PKR to relocalize 486 
both to the nucleus and to cytoplasmic P bodies (13). At present, the role of nuclear 487 
accumulation of PKR in infected cells is unknown, but it might serve to keep PKR away 488 
from its cytoplasmic targets, or alternatively, to enable interaction with a nuclear target 489 
and enhance viral replication.  The relocalization of PKR into insoluble cytoplasmic 490 
compartments might represent another mechanism for ensuring PKR is sequestered away 491 
from translational machinery.  Note that our glycerol gradient experiments would not 492 
have detected nuclear or insoluble cytoplasmic complexes since these were removed 493 
during processing, so it remains possible that pm142 and pm143 are associated with PKR 494 
in these sites.  Consistent with this possibility, Hanson et al. found that pm142 and 495 
pm143 appear to be primarily cytoplasmic by immunofluorescence, but were present in 496 
the “nuclear” fractions as well when analyzed by cell fractionation and immunoblot assay 497 
(12).  498 
 Our data suggest that pm142 and pm143 form a stable complex, likely a 499 
heterotetramer, consisting of two molecules of pm142 associated with each other and 500 
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each one associating with a molecule of pm143 (Fig 10).  Data supporting this proposed 501 
structure include the observations that in infected cells, pm142 and pm143 (i) colocalize 502 
by immunofluorescence (12), (ii) coimmunoprecipitate (Fig. 1 and (7)), and (iii) migrate 503 
through glycerol gradients as a complex having a size consistent with a heterotetramer 504 
(Fig. 4).  Further evidence comes from transfection assays showing that (iv) pm143 505 
stability requires pm142, (v) the molarity of the two proteins in the complex is similar 506 
(based on experiments in which their relative amounts can be compared, as in Figs. 2A, 507 
Fig. 5, and Fig. 6) and (vi) pm142 can self-associate while pm143 appears not to do so 508 
(Fig. 7).   509 
 Based on our results, we propose a model in which pm142 and pm143 form a 510 
stable soluble heterotetrameric cytoplasmic complex during infection (Fig. 10).  This 511 
complex serves as a reservoir, poised to interact with PKR and dsRNA.  As has been 512 
proposed for the mechanism by which E3L functions, the pm142:pm143 complex may 513 
associate with PKR and prevent its homodimerization (24). The absence of a stable 514 
soluble pm142:pm143:PKR complex may result from its relocalization to the nucleus and 515 
insoluble cytoplasmic fractions where PKR would be unable to shut off translation, 516 
although it is also possible that a transient interaction with pm142 and pm143 is sufficient 517 
to cause PKR to relocalize.  Although we do not yet understand the significance of the 518 
separation of PKR inhibitory function into two proteins in MCMV, this organization is 519 
unique among viruses studied thus far, and we expect that further exploration of this 520 
system will help uncover fundamentals of the mechanisms by which dsRNA-binding 521 
proteins interfere with PKR function and enable viral replication.  522 
 523 
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 FIGURE LEGENDS 631 
 632 
Figure 1.  The pm142 and pm143 proteins bind PKR in MCMV-infected cells.  NIH 3T3 633 
cells were mock-infected (lanes 1, 3, 4, and 5) or infected with MCMV (lanes 2, 6, 7 and 634 
8; MOI = 3), and at 48 h post-infection lysates were prepared and analyzed by 635 
immunoblot assay directly (lanes 1 and 2) or after immunoprecipitation with the 636 
preimmune serum (lanes 3 and 6), pm142 antiserum (lanes 4 and 7) or pm143 antiserum 637 
(lanes 5 and 8).  (A) Unbound mock and infected cell lysates (lanes 1 and 2; 3% of the 638 
amount immunoprecipitated) and 20% of each bound sample (lanes 3 – 8) were probed 639 
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using a mixture of m142 and m143 antisera.  The migration of pm142, pm143, and the 640 
IgG heavy chain (HC) are indicated on the right.  (B) Lysates and the remaining 80% of 641 
each bound sample were probed with the anti-PKR antibody.   642 
 643 
Figure 2.  Both pm142 and pm143 bind to PKR in transfected cells.  HeLa cells were 644 
transfected with the indicated plasmids, all of which express proteins containing His tags 645 
alone (-H) or with a biotinylation signal (-B-H).  All transfections, except that in lane 4, 646 
also included the plasmid encoding biotin ligase (pSC2+BirA).  At 48 h post-transfection 647 
cell lysates were prepared and incubated with AV-agarose and analyzed by immunoblot 648 
assay as described in Materials and Methods.  (A) Membranes with unbound lysates (top 649 
panel) or 20% of the bound samples (bottom panel) were probed with the anti-His 650 
antibody.  (B) Membranes with unbound lysate (top panel) and 80% of the bound 651 
samples (lower panel) were subjected to immunoblot analysis with the PKR antibody.  652 
 653 
Figure 3.  The pm143 protein is stabilized by co-expression of pm142.  HeLa cells were 654 
transiently transfected with m143-B-H alone or in combination with m142-H.  At 24 h 655 
post-transfection the cells were pulse labeled with [35S]methionine for 1 h then re-fed 656 
with medium containing excess cold methionine.  Cell lysates were prepared at the 657 
indicated times post-chase and proteins binding to AV-agarose were analyzed by 658 
electrophoresis and phosphorimager analysis.   659 
 660 
Figure 4.  Size fractionation of pm142:pm143 complexes and PKR on glycerol density 661 
gradients.  NIH 3T3 cells were infected with MCMV (MOI = 3), and at 48 h post-662 
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infection cell lysates were prepared and centrifuged through 15-35% glycerol density 663 
gradients as described in Materials and Methods.  Following centrifugation, fractions 664 
were collected from the bottom of the gradients, and the fractions were separated on 665 
polyacrylamide gels, transferred to PVDF, and probed with (A) a mixture of m142 and 666 
m143 antisera, after which the blot was stripped and re-probed with (B) an anti-PKR 667 
antibody.  Molecular weight standards were size fractionated on a parallel gradient, then 668 
analyzed by polyacrylamide gel electrophoresis and Coomassie blue staining.  The 669 
migration of the molecular weight standards is indicated below panel B.  Note that 670 
fractions 5 and 7 were lost during processing and that aliquots of the lysates (lys) prior to 671 
fractionation were included in the first and last lanes.  672 
 673 
Figure 5.  The pm142:pm143 complex does not contain additional MCMV proteins.  674 
HeLa cells were transfected with plasmids expressing BirA, m142-B-H and m143-B-H, 675 
and at 24 h post-transfection lysates were prepared and fractionated on 15-35% glycerol 676 
density gradients as described in Materials and Methods.  The indicated subset of 677 
fractions were analyzed by gel electrophoresis, transfer to PVDF, and detection of the 678 
biotin-tagged pm142 and pm143 proteins using avidin-AP.  The migration of molecular 679 
weight standards analyzed on a parallel gradient is indicated below.    680 
 681 
Figure 6.  The pm142:pm143 complex does not include cellular proteins.  HeLa cells 682 
were transfected with plasmids expressing m143-B-H and m142-H, TRS1-B-H, or m143-683 
H plus m142-H.  All samples also included pSC2+BirA.  At 48 h post-transfection 684 
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lysates were prepared and incubated with AV-agarose as described in Materials and 685 
Methods, and bound proteins were analyzed by gel electrophoresis and silver staining.   686 
 687 
Figure 7.  The pm142 and pm143 proteins appear to form a heterotetrameric complex.  688 
HeLa cells were transfected with pSC2+BirA in addition to the indicated plasmids that 689 
express either His- or biotin-tagged forms of pm142 and pm143.  At 48 h post-690 
transfection lysates were collected, incubated with avidin-agarose, and subjected to 691 
immunoblot analysis as previously described. Membranes containing (A) unbound 692 
lysates (3% of total) and (B) 50% of the bound samples (bottom panel) were probed with 693 
anti-His antibody.  Membranes with (C) unbound (3% of total) and (D) bound lysates 694 
(50% of total) were probed with avidin-AP to detect biotin-tagged proteins.   695 
 696 
Figure 8.  MCMV infection causes nuclear relocalization of PKR.  NIH 3T3 cells were 697 
mock-infected or infected with MCMV (MOI = 3).  Cell lysates were prepared at 24, 48, 698 
and 72 h post-infection and separated into cytoplasmic- (cyt) and nuclear-enriched (nuc) 699 
fractions as described in Materials and Methods.  Equal amounts of each fraction were 700 
subjected to gel electrophoresis, transferred to PVDF membranes, and probed with the 701 
indicated antisera including the nuclear marker lamin A/C and the cytoplasmic marker 702 
calnexin.   703 
 704 
Figure 9.  MCMV infection appears to cause PKR relocalization to both the nucleus and 705 
insoluble cytoplasmic complexes.  NIH 3T3 and PKR null cells grown on coverslips were 706 
mock-infected or infected with MCMV (MOI = 3).  At 48 h post-infection the cells were 707 
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fixed, incubated with anti-PKR or an isotype control antibody, and prepared for 708 
immunofluorescence as described in Materials and Methods.  Samples were analyzed by 709 
deconvolution microscopy.   710 
 711 
Figure 10.  Model depicting putative mechanisms of PKR inactivation and re-712 
localization by pm142 and pm143.  In the absence of viral antagonists (1), PKR is 713 
activated by dsRNA, which leads to dimerization, auto-phosphorylation, and subsequent 714 
phosphorylation of the alpha subunit of the translation initiation factor eIF2, thereby 715 
blocking translation and inhibiting viral replication.  During MCMV infection, a stable 716 
heterotetrameric pm142:pm143 complex forms which can interact with PKR and dsRNA. 717 
(2),  Whether or not pm142 and pm143 remain associated with PKR is not yet clear but 718 
we hypothesize that these viral proteins cause sequestration of PKR in the nucleus and in 719 
insoluble cytoplasmic complexes (gray area) where it is unlikely to be able to shut off 720 
translation and block viral replication. 721 










